lung cancer

News

Merck & Co axes Keytruda lung cancer niche amid FDA crackdow...

Merck & Co has voluntarily withdrawn its Keytruda immunotherapy from a lung cancer niche in the US, amid a crackdown by the FDA on drugs approved without the required post-marketing dat

News

NICE backs NHS funding for MSD's Keytruda combination in lun...

NICE has backed regular NHS funding England and Wales for Merck, Sharp and Dohme’s Keytruda in combination with pemetrexed and platinum chemotherapy in certain lung cancer patients.

Views & Analysis

Not every cough is COVID – MSD UK’s lung cancer campaign

For World Cancer Day, David Long, business unit director of Oncology at MSD UK tells pharmaphorum about the company’s ‘Do It Yourself’ campaign launched in the North East to raise awareness

News

AZ/Daiichi Sankyo's partnership makes progress in lung cance...

AstraZeneca and Daiichi Sankyo have announced data from two drugs in lung cancer, which they are developing as part of their ongoing partnership.

News

Doctors warn pandemic has pushed lung cancer services back 2...

Governments must act to restore the damage done to lung cancer services during the pandemic in order to reduce further avoidable deaths, according to a report drawn up as part of this week'

News

GSK/Merck's hopeful bintrafusp alfa fails in key lung cancer...

GlaxoSmithKline’s big gamble on a cancer drug developed by Germany’s Merck KGaA looks unlikely to pay out, after bintrafusp alfa failed to outperform US-based Merck & Co’s Keytruda in a

Merck & Co axes Keytruda lung cancer niche amid FDA crackdow...

NICE backs NHS funding for MSD's Keytruda combination in lun...

Not every cough is COVID – MSD UK’s lung cancer campaign

AZ/Daiichi Sankyo's partnership makes progress in lung cance...

Doctors warn pandemic has pushed lung cancer services back 2...

GSK/Merck's hopeful bintrafusp alfa fails in key lung cancer...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

lung cancer

Editor's Picks